Nonetheless, the advantage of our study is that we comprehensively compared the efficacies and adverse events of the three main treatments of advanced/metastatic PC: radiotherapy, endocrine therapy (estrogen therapy, LHRH-A, ADT, ADT + LHRH-A and estrogen therapy + LHRH-A) and radiotherapy + estrogen therapy. The gene discussed is GNRH1; the disease is pachyonychia congenita.